Yuan-Ling Cheng

Yuan-Ling Cheng

Auto-generated profile, based on publicly available information

Yuan-Ling Cheng

Division of Urology, Department of Surgery Tri‐Service General Hospital, National Defense Medical Center Taipei Taiwan, ROC

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Thoracic Cancer
Verified
Journal Article
Open access
YCYuan‐Ling Cheng
Yuan‐Ling Cheng
WCWei‐Kuo Chang
Wei‐Kuo Chang
HYHao Yen
Hao Yen
YPYi‐Jen Peng
Yi‐Jen Peng
WCWei‐Chou Chang
Wei‐Chou Chang
PCPing-Ying Chang
Ping-Ying Chang
Osimertinib is approved as the first‐line treatment for advanced non‐small cell lung cancer patients with epidermal growth factor (EGFR) mutation and for patients who develop EGFR T790M mutation during EGFR tyrosine kinase inhibitor (TKI) treatment and disease progression. Asymptomatic elevation of aminotransferase levels is commonly observed during TKI treatment; however, significant hepatotoxicity is infrequent. Here, we report a patient with osimertinib‐related drug‐induced liver injury who was successfully managed with osimertinib rechallenge.

22 October 2026 in Asian Journal of Surgery
Verified
Journal Article
Open access
YCYuan-Ling Cheng
Yuan-Ling Cheng
CTChih-Wei Tsao
Chih-Wei Tsao
GSGuang-Huan Sun
Guang-Huan Sun
HTHui-Kung Ting
Hui-Kung Ting